The National Health Surveillance Agency (Anvisa) formalized a series of preventive measures against the sale of Cannabis products this Wednesday (11/19/2025). The Resolution-RE No. 4,641, published in the Official Gazette of the Union, determines the immediate prohibition of commercialization and seizure of irregular items.

The company Healthycann Brasil Ltda is among the main ones affected by the new resolution. Anvisa determined the prohibition of manufacturing, distribution, and advertising of all batches of its Cannabis products, including the lines "HC Full Spectrum" and "HC Focus".

According to the agency, the measure was motivated by evidence of sales announcements without the proper sanitary regularization. The company did not have authorization to manufacture or import items from these regulatory categories.

In a statement, the company stated that it continues its activities within legal limits, ethically and responsibly, strictly observing the rules governing the sector.

"All appropriate measures have already been taken, including immediate adjustments to our communication channels and the implementation of new internal procedures that reinforce transparency and regulatory alignment of the company," it concludes.

Official Statement - HealthyCann Brasil Ltda, registered under CNPJ No. 49,430,137/0001-75, comes forward to provide clarifications regarding Resolution-RE No. 4,641, of 11/18/2025, published in the Official Gazette of the Union, reaffirming its commitment to legality, transparency, and regulatory compliance in all its activities. The company operates exclusively in providing technical and regulatory guidance services to legally prescribed patients, without any manufacturing, distribution, importation, storage, or commercialization of products subject to health surveillance.

We reiterate our absolute commitment to technical regularity, patient safety, and full compliance with Brazilian health legislation. HealthyCann's activities have always been carried out within legal limits, ethically and responsibly, strictly observing the rules governing the sector.

All appropriate measures have already been taken, including immediate adjustments to our communication channels and the implementation of new internal procedures that reinforce transparency and regulatory alignment of the company.

HealthyCann Brasil remains entirely available to the competent authorities and patients, reaffirming its commitment to ethics, responsibility, and total legal compliance.